Please login to the form below

Not currently logged in
Email:
Password:

Kevin Sin joins GSK

He becomes senior VP, head of worldwide business development

Kevin SinKevin Sin has joined GlaxoSmithKline as its senior vice president, head of worldwide business development for pharmaceutical research and development.

In this position, Sin will play a role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of new medicines for patients.

He said: “The incredible pace of scientific and technical innovation that is happening around the world is significant and presents an abundance of opportunities to combine GSK’s strengths and capabilities with that of others to pursue big ideas in science and medicine.

“I look forward to working with the team to explore collaborations that can accelerate the discovery and development of new medicines with the potential to significantly improve human health.”

Sin joins GSK from Genetech, where he served as vice president and global head of oncology business development and has worked within the pharmaceutical and life science industry for over 20 years.

Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. Gaining access to the best science and technologies across the world as well as establishing highly productive collaborations with academia and industry, play an important role in creating a world-class R&D organization.

“Kevin’s leadership skills, significant expertise and successful track record make him the ideal person to lead Business Development activities for R&D.”

Sin will report to Hal Barron and will be based at the group’s San Francisco office.

1st June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

CBC
Building Europe’s next breakthrough biotechs
Start Codon's Daniel Rooke on fostering biotech success in Cambridge, UK...
Tactful screening & participant sensitivity
Screening participants can involve asking personal questions that could be perceived as intrusive. Here CMR explores the implications of such lines of questioning....
Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...

Infographics